Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly.

Glodzik L, Rusinek H, Pirraglia E, McHugh P, Tsui W, Williams S, Cummings M, Li Y, Rich K, Randall C, Mosconi L, Osorio R, Murray J, Zetterberg H, Blennow K, de Leon M.

Neurobiol Aging. 2014 Jan;35(1):64-71. doi: 10.1016/j.neurobiolaging.2013.06.011.

2.

Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease.

Henneman WJ, Vrenken H, Barnes J, Sluimer IC, Verwey NA, Blankenstein MA, Klein M, Fox NC, Scheltens P, Barkhof F, van der Flier WM.

Neurology. 2009 Sep 22;73(12):935-40. doi: 10.1212/WNL.0b013e3181b879ac.

3.

Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders.

Glodzik L, de Santi S, Tsui WH, Mosconi L, Zinkowski R, Pirraglia E, Wang HY, Li Y, Rich KE, Zetterberg H, Blennow K, Mehta P, de Leon MJ.

Neurobiol Aging. 2011 Dec;32(12):2131-41. doi: 10.1016/j.neurobiolaging.2009.12.026.

4.

Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects.

Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Jack CR Jr, Aisen PS, Petersen RC, Weiner MW; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2010 Nov 30;75(22):1976-81. doi: 10.1212/WNL.0b013e3181ffe4d1.

5.

Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.

Pettigrew C, Soldan A, Moghekar A, Wang MC, Gross AL, O'Brien R, Albert M.

Neuropsychologia. 2015 Nov;78:63-72. doi: 10.1016/j.neuropsychologia.2015.09.024.

6.

MRI and CSF studies in the early diagnosis of Alzheimer's disease.

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.

J Intern Med. 2004 Sep;256(3):205-23.

7.

Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults.

Nation DA, Edmonds EC, Bangen KJ, Delano-Wood L, Scanlon BK, Han SD, Edland SD, Salmon DP, Galasko DR, Bondi MW; Alzheimer’s Disease Neuroimaging Initiative Investigators..

JAMA Neurol. 2015 May;72(5):546-53. doi: 10.1001/jamaneurol.2014.4477.

8.

Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults.

Nation DA, Edland SD, Bondi MW, Salmon DP, Delano-Wood L, Peskind ER, Quinn JF, Galasko DR.

Neurology. 2013 Dec 3;81(23):2024-7. doi: 10.1212/01.wnl.0000436935.47657.78.

9.

Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.

Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM.

JAMA Neurol. 2015 Jun;72(6):656-65. doi: 10.1001/jamaneurol.2015.0202.

10.

Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.

Schmand B, Huizenga HM, van Gool WA.

Psychol Med. 2010 Jan;40(1):135-45. doi: 10.1017/S0033291709991516.

PMID:
19863841
11.

Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.

Wang L, Benzinger TL, Hassenstab J, Blazey T, Owen C, Liu J, Fagan AM, Morris JC, Ances BM.

Neurology. 2015 Mar 24;84(12):1254-60. doi: 10.1212/WNL.0000000000001401.

12.

CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.

Neurology. 2009 Oct 27;73(17):1353-8. doi: 10.1212/WNL.0b013e3181bd8271.

PMID:
19858456
13.

Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.

Paternicò D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, Baronio M, Amicucci G, Frisoni GB.

Alzheimers Dement. 2012 Nov;8(6):520-7. doi: 10.1016/j.jalz.2011.10.003.

PMID:
22677492
14.

Systolic blood pressure within an intermediate range may reduce memory loss in an elderly hypertensive cohort.

Sacktor N, Gray S, Kawas C, Herbst J, Costa P, Fleg J.

J Geriatr Psychiatry Neurol. 1999 Spring;12(1):1-6.

PMID:
10447147
15.

Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.

Kester MI, Goos JD, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, Barkhof F, Scheltens P, van der Flier WM.

JAMA Neurol. 2014 Jul 1;71(7):855-62. doi: 10.1001/jamaneurol.2014.754.

PMID:
24818585
16.

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, McCulloch C, Ptok U, Heun R, Andreasen N, DeBernardis J, Kerkman D, Moeller H, Davies P, Hampel H.

Neurology. 2002 Aug 27;59(4):627-9. Erratum in: Neurology. 2004 Sep 28;63(6):1144.

PMID:
12196665
17.

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H.

Brain. 2006 Nov;129(Pt 11):3035-41.

PMID:
17012293
18.

Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study.

Aschenbrenner AJ, Balota DA, Fagan AM, Duchek JM, Benzinger TL, Morris JC.

J Int Neuropsychol Soc. 2015 Sep;21(8):573-83. doi: 10.1017/S1355617715000776.

19.

Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients.

Wahlund LO, Blennow K.

Neurosci Lett. 2003 Mar 20;339(2):99-102.

PMID:
12614904
20.

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

Stomrud E, Hansson O, Blennow K, Minthon L, Londos E.

Dement Geriatr Cogn Disord. 2007;24(2):118-24.

PMID:
17622715
Items per page

Supplemental Content

Support Center